TherapeuticsMD Inc. (NASDAQ: TXMD) reported a net loss from continuing operations of $0.7 million for the year ended December 31, 2025, translating to a loss of $0.06 per share. The loss is a sharp improvement over the $2.3 million net loss recorded for 2024, reflecting a 30 % reduction in operating expenses and a 67 % increase in license revenue.
Operating expenses fell 5.9 % to $7.4 million from $7.9 million in 2024, while license revenue climbed to $3.0 million from $1.8 million. The company’s transition to a royalty‑only model has shifted the cost structure, allowing it to reduce overhead while capturing a larger share of its license income. The narrowing loss is therefore driven primarily by cost discipline and higher royalty inflows rather than a rebound in product sales.
Despite the improved loss profile, the company continues to face significant headwinds. A pending litigation with Mayne Pharma over working‑capital allowances introduces uncertainty about future cash flows, and the filing notes that the company may not be able to continue as a going concern without additional financing or a strategic transaction. Cash and cash equivalents stood at $7.5 million as of December 31, 2025, a modest cushion that underscores the need for liquidity support.
Management reiterated that it is actively evaluating a range of strategic alternatives, including potential acquisitions, mergers, asset sales, or other business combinations. The company’s leadership has emphasized that these options are being explored to secure a sustainable long‑term business model and to address the liquidity constraints highlighted in the filing.
The full‑year results, while showing a narrowed loss, highlight the company’s ongoing struggle to generate positive earnings under its current royalty‑only structure. Investors will likely monitor the company’s progress in resolving litigation risks, securing additional capital, and executing a viable strategic plan to move beyond the current loss position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.